Meeting NewsVideo

VIDEO: Combination regimen ‘viable, effective’ for follicular lymphoma

CHICAGO — Jeremy Slade Abramson, MD, clinical director of the Center for Lymphoma at Massachusetts General Hospital Cancer Center, provided perspective on the phase 3b MAGNIFY trial presented at the ASCO Annual Meeting, which showed promise for the combination of lenalidomide and rituximab for follicular lymphoma.

The multicenter, open-label trial evaluated 12 cycles of the combination in patients with follicular lymphoma who were double refractory or had early relapse after initial diagnosis. Sixty-six percent of patients achieved 1-year PFS.

“What these data tell us is that in follicular lymphoma, relapsing after initial chemotherapy-immunotherapy validates the combination of rituximab plus lenalidomide as a viable, effective and tolerable option for those patients,” Abramson said. “Further, it provides the very first data of this regimen in the high-risk subset of early-relapse patients where it also appears to be inducing encouraging responses, many of which are sustained at least 1 year after initial treatment.” – by Kristie L. Kahl

Disclosure: Abramson reports no relevant financial disclosures.

CHICAGO — Jeremy Slade Abramson, MD, clinical director of the Center for Lymphoma at Massachusetts General Hospital Cancer Center, provided perspective on the phase 3b MAGNIFY trial presented at the ASCO Annual Meeting, which showed promise for the combination of lenalidomide and rituximab for follicular lymphoma.

The multicenter, open-label trial evaluated 12 cycles of the combination in patients with follicular lymphoma who were double refractory or had early relapse after initial diagnosis. Sixty-six percent of patients achieved 1-year PFS.

“What these data tell us is that in follicular lymphoma, relapsing after initial chemotherapy-immunotherapy validates the combination of rituximab plus lenalidomide as a viable, effective and tolerable option for those patients,” Abramson said. “Further, it provides the very first data of this regimen in the high-risk subset of early-relapse patients where it also appears to be inducing encouraging responses, many of which are sustained at least 1 year after initial treatment.” – by Kristie L. Kahl

Disclosure: Abramson reports no relevant financial disclosures.

    See more from ASCO Annual Meeting